`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`____________________________________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`____________________________________________
`
`
`TWI PHARMACEUTICALS, INC.,
`Petitioner,
`
`v.
`
`MERCK SERONO SA,
`Patent Owner.
`
`____________________________________________
`
`Case IPR2023-00049
`U.S. Patent No. 7,713,947
`____________________________________________
`
`PATENT OWNER’S UPDATE TO MANDATORY NOTICES
`UNDER 37 C.F.R. § 42.8
`
`
`
`
`
`
`
`Patent Owner’s Update to Mandatory Notices
`IPR2023-00049
`
`
`Pursuant to 37 C.F.R. § 42.8, Patent Owner respectfully submits the
`
`following updated related matters for its Mandatory Notices.
`
`I.
`
`37 C.F.R. § 42.8(b)(2) – Related Matters
`
`U.S. Patent No. 7,713,947 (“the ’947 patent”) is a patent-in-suit in the
`
`following litigations: Merck KGaA, Merck Serono SA, and Ares Trading SA v.
`
`Accord Healthcare, Inc., No. 1:22-cv-00974-GBW (D. Del.), Merck KGaA, Merck
`
`Serono SA, and Ares Trading SA v. Hopewell Pharma Ventures, Inc., No. 1:22-cv-
`
`01365-GBW (D. Del.), and Merck KGaA, Merck Serono SA, and Ares Trading SA
`
`v. Aurobindo Pharma USA, Inc. and Aurobindo Pharma Limited, No. 1:23-cv-
`
`00039-GBW (D. Del.).
`
`The ’947 patent is related to U.S. Patent No. 8,377,903 (“the ’903 patent”),
`
`which issued from an application that was filed as a continuation of the ’947
`
`patent. Petitioner concurrently filed a petition for inter partes review of the ’903
`
`patent as proceeding no. IPR2023-00050.
`
`On January 23, 2023, Hopewell Pharma Ventures, Inc. (“Hopewell”), filed
`
`petitions for inter partes review of the ’947 and ’903 patents as proceeding nos.
`
`IPR2023-00480 and IPR2023-00481, respectively. On February 10, 2023,
`
`Hopewell filed a petition for inter partes review of U.S. Patent No. 10,849,919
`
`(“the ’919 patent”) as proceeding no. IPR2023-00482. The ’919 patent is assigned
`
`to Ares Trading SA and is a patent-in-suit in the judicial matters identified above.
`
`
`
`1
`
`
`
`Date: February 23, 2023
`
`
`
`
`
`
`Patent Owner’s Update to Mandatory Notices
`IPR2023-00049
`
`
`Respectfully submitted,
`
`By: /Deric X. Geng/
`Deric X. Geng, Ph.D. (Reg. No. 73,434)
`Wilmer Cutler Pickering Hale and Dorr LLP
`60 State Street
`Boston, MA 02109
`Tel: (617) 526-6026
`Email: Deric.Geng@wilmerhale.com
`
`2
`
`
`
`Patent Owner’s Update to Mandatory Notices
`IPR2023-00049
`
`CERTIFICATE OF SERVICE
`
`I hereby certify that on February 23, 2023, I caused a true and correct copy
`
`of the following document:
`
` Patent Owner’s Update to Mandatory Notices Under 37 C.F.R. § 42.8
`
`to be served via e-mail, as consented to by Petitioner, on the following attorneys of
`
`record:
`
`Philip.Segrest@huschblackwell.com
`Nathan.Sportel@huschblackwell.com
`Steve.Howe@huschblackwell.com
`
`
`
`By: /Cindy Kan/
`
`Cindy Kan (Reg. No. 76,385)
`Wilmer Cutler Pickering Hale and Dorr LLP
`7 World Trade Center
`250 Greenwich Street
`New York, NY 10007
`Tel: 212-295-6470
`Email: cindy.kan@wilmerhale.com
`
`
`
`3
`
`